{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:45:08Z","timestamp":1761864308457,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"13-14","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010878","name":"AbbVie Biotherapeutics","doi-asserted-by":"publisher","award":["This study was supported by an unrestricted grant from AbbVie to TR."],"award-info":[{"award-number":["This study was supported by an unrestricted grant from AbbVie to TR."]}],"id":[{"id":"10.13039\/100010878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>Recent reports suggest an increasing incidence of hepatitis\u00a0C virus (HCV) infections among MSM (men-who-have-sex-with-men). Early treatment with direct-acting antivirals (DAAs) achieves high cure rates and prevents further HCV transmission. We offered barrier-free HCV screening in the Viennese MSM population and immediate access to DAA treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In collaboration with gay health specialists, we screened for HCV seropositivity in Viennese MSM between 2019 and 2020. Barrier-free HCV-RNA-PCR tests, transient elastography (TE) and immediate access to DAA treatment were offered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 310 HCV-seropositive patients were identified. Of those, 145 could be contacted and 109 attended their appointment at our clinic. HIV-coinfection was highly prevalent in our cohort (<jats:italic>n<\/jats:italic>\u202f=\u200986\/145; 78.9%), while pre-exposure prophylaxis (PrEP) was taken by 21.7% (<jats:italic>n<\/jats:italic>\u202f=\u20095\/23) of non-HIV patients. Sexual risk behavior and (history of) intravenous drug use was reported by 32.1% and 13.8% of patients, respectively. Most MSM had already achieved sustained virological response (SVR) to previous antiviral treatment (<jats:italic>n<\/jats:italic>\u202f=\u200972, 66.1%) or experienced spontaneous clearance (<jats:italic>n<\/jats:italic>\u202f=\u200910, 9.2%). Advanced fibrosis was only detected in 3\/109 (2.8%) patients. 30\u00a0MSM tested positive for HCV-RNA and DAA treatment was initiated in 29\u00a0patients\u00a0\u2013 all achieved SVR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A\u00a0targeted HCV test-and-treat program revealed a\u00a0high prevalence of HCV seropositivity among Viennese MSM, potentially associated with high-risk sexual behavior and drug use. Early DAA treatment seems warranted in viremic HCV-MSM as SVR was 100%, which in turn prevents further HCV transmission.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00508-021-01898-9","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T11:05:20Z","timestamp":1624878320000},"page":"635-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes of an HCV elimination program targeting the Viennese MSM population"],"prefix":"10.1007","volume":"133","author":[{"given":"Mathias","family":"Jachs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Binter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chromy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlheinz","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Simbrunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Schmidbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Strassl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gschwantler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"issue":"4","key":"1898_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/2050640619835394","volume":"7","author":"D Chromy","year":"2019","unstructured":"Chromy\u00a0D, Mandorfer\u00a0M, Bucsics\u00a0T, et al. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United European Gastroenterol\u00a0J. 2019;7(4):507\u201316.","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"1898_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/liv.14399","volume":"40","author":"C Schmidbauer","year":"2020","unstructured":"Schmidbauer\u00a0C, Chromy\u00a0D, Schmidbauer\u00a0V, et\u00a0al. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver Int. 2020;40(4):787\u201396.","journal-title":"Liver Int"},{"issue":"8","key":"1898_CR3","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/QAD.0000000000001789","volume":"32","author":"P Pradat","year":"2018","unstructured":"Pradat\u00a0P, Huleux\u00a0T, Raffi\u00a0F, et\u00a0al. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. AIDS. 2018;32(8):1077\u201382.","journal-title":"AIDS"},{"issue":"2","key":"1898_CR4","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/S2352-3018(20)30301-5","volume":"8","author":"C Smit","year":"2021","unstructured":"Smit\u00a0C, Boyd\u00a0A, Rijnders\u00a0BJA, et al. HCV micro-elimination in individuals with HIV in the Netherlands 4\u00a0years after universal access to direct-acting antivirals: a\u00a0retrospective cohort study. Lancet HIV. 2021;8(2):e96\u2013e105.","journal-title":"Lancet HIV"},{"issue":"10","key":"1898_CR5","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/liv.13922","volume":"38","author":"L Cotte","year":"2018","unstructured":"Cotte\u00a0L, Cua\u00a0E, Reynes\u00a0J, et al. Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. Liver Int. 2018;38(10):1736\u201340.","journal-title":"Liver Int"},{"issue":"1","key":"1898_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S2468-1253(20)30303-4","volume":"6","author":"F Jin","year":"2021","unstructured":"Jin\u00a0F, Dore\u00a0GJ, Matthews\u00a0G, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a\u00a0systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(1):39\u201356.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1898_CR7","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/cid\/ciz948","volume":"71","author":"D Chromy","year":"2020","unstructured":"Chromy\u00a0D, Schmidt\u00a0R, Mandorfer\u00a0M, et\u00a0al. Hepatitis C virus RNA is commonly detectable in rectal and nasal fluids of patients with high viremia. Clin Infect Dis. 2020;71(5):1292\u20139.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1898_CR8","doi-asserted-by":"publisher","first-page":"ofy238","DOI":"10.1093\/ofid\/ofy238","volume":"5","author":"PM Palaniswami","year":"2018","unstructured":"Palaniswami\u00a0PM, El Sayed\u00a0A, Asriel\u00a0B, Carollo\u00a0JR, Fierer\u00a0DS. Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men. Open Forum Infect Dis. 2018;5(10):ofy238.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1898_CR9","doi-asserted-by":"publisher","first-page":"e0210179","DOI":"10.1371\/journal.pone.0210179","volume":"14","author":"S Popping","year":"2019","unstructured":"Popping\u00a0S, Hullegie\u00a0SJ, Boerekamps\u00a0A, et al. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One. 2019;14(1):e210179.","journal-title":"PLoS One"},{"issue":"1","key":"1898_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jvh.12752","volume":"25","author":"L Salazar-Vizcaya","year":"2018","unstructured":"Salazar-Vizcaya\u00a0L, Kouyos\u00a0RD, Fehr\u00a0J, et al. On the potential of a\u00a0short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study. J\u00a0Viral Hepat. 2018;25(1):10\u20138.","journal-title":"J Viral Hepat"},{"issue":"5","key":"1898_CR11","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"EASL","year":"2020","unstructured":"EASL. EASL recommendations on treatment of hepatitis C: final update of the series(\u2606). J\u00a0Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"issue":"9-10","key":"1898_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00508-020-01790-y","volume":"133","author":"L Steininger","year":"2020","unstructured":"Steininger\u00a0L, Chromy\u00a0D, Bauer\u00a0D, et al. Direct patient-physician communication via a\u00a0hepatitis\u00a0C hotline facilitates treatment initiation in patients with poor adherence. Wien Klin Wochenschr. 2020;133(9-10):452\u201360.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"1898_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"EASL","year":"2018","unstructured":"EASL. EASL recommendations on treatment of hepatitis C 2018. J\u00a0Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"2","key":"1898_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra\u00a0L, Vergniol\u00a0J, Foucher\u00a0J, et\u00a0al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343\u201350.","journal-title":"Gastroenterology"},{"issue":"3","key":"1898_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12072-015-9691-4","volume":"10","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer\u00a0M, Schwabl\u00a0P, Steiner\u00a0S, Reiberger\u00a0T, Peck-Radosavljevic\u00a0M. Advances in the management of HIV\/HCV coinfection. Hepatol Int. 2016;10(3):424\u201335.","journal-title":"Hepatol Int"},{"key":"1898_CR16","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. Geneva: World Health Organization; 2016."},{"issue":"7","key":"1898_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1097\/QAD.0000000000001020","volume":"30","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer\u00a0M, Schwabl\u00a0P, Steiner\u00a0S, et al. Interferon-free treatment with sofosbuvir\/daclatasvir achieves sustained virologic response in 100\u202f% of HIV\/hepatitis C virus-coinfected patients with advanced liver disease. Aids. 2016;30(7):1039\u201347.","journal-title":"Aids"},{"issue":"7","key":"1898_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41575-018-0026-5","volume":"15","author":"M Martinello","year":"2018","unstructured":"Martinello\u00a0M, Hajarizadeh\u00a0B, Grebely\u00a0J, Dore\u00a0GJ, Matthews\u00a0GV. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 2018;15(7):412\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3-4","key":"1898_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00508-017-1231-x","volume":"130","author":"D Chromy","year":"2018","unstructured":"Chromy\u00a0D, Schwabl\u00a0P, Bucsics\u00a0T, et al. Non-invasive liver fibrosis assessment and HCV treatment initiation within a\u00a0systematic screening program in HIV\/HCV coinfected patients. Wien Klin Wochenschr. 2018;130(3-4):105\u201314.","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"1898_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/apt.13315","volume":"42","author":"M Mandorfer","year":"2015","unstructured":"Mandorfer\u00a0M, Kozbial\u00a0K, Freissmuth\u00a0C, et al. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Aliment Pharmacol Ther. 2015;42(6):707\u201318.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01898-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-021-01898-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01898-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T10:43:43Z","timestamp":1626777823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-021-01898-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":20,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1007\/s00508-021-01898-9","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.\u00a0Jachs, T.\u00a0Binter, H.\u00a0Schalk, K.\u00a0Pichler, C.\u00a0Schmidbauer, L.\u00a0Hartl, and R.\u00a0Strassl, declare that they have no competing interests. D.\u00a0Chromy served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, Gilead, and MSD, and received travel support from AbbVie, MSD, VilV Healthcare, and Gilead. D.\u00a0Bauer has received travel support from AbbVie and Gilead, as well as speaker fees from AbbVie. B.\u00a0Simbrunner has received travel support from AbbVie and Gilead. M.\u00a0Mandorfer served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, Collective Acumen, and W. L. Gore & Associates and received travel support from AbbVie, Bristol-Myers Squibb, and Gilead. M.\u00a0Gschwantler received grants from AbbVie, Gilead, and MSD; speaker fees from AbbVie, Gilead, MSD, Janssen, Roche, Intercept and consulting\/advisory board fees from AbbVie, Gilead, MSD, Janssen, Roche and intercept T.\u00a0Reiberger served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, Intercept, MSD, Siemens, and W. L. Gore & Associates and received grants\/research support from AbbVie, Boehringer Ingelheim, Gilead, MSD, Philips, and W. L. Gore & Associates as well as travel support from Boehringer Ingelheim and Gilead. F.\u00a0Mayer has received research support from Roche Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee of the Medical University of Vienna (EC Vote No. 1968\/2018). No written informed consent was required for this retrospective analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}